EPIGENOMICS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.512 EUR | -0.26% |
|
+0.27% | -41.03% |
| Sales 2024 * | 150K 160K | Sales 2025 * | - | Capitalization | 1.42M 1.52M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | -4.77 x |
| Net cash position 2024 * | 2.14M 2.28M | Net cash position 2025 * | 1.69M 1.8M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.44
x | P/E ratio 2025 * |
-2.46
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| 1 day | -0.26% |
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.635
EUR
Average target price
16.85
EUR
Spread / Average Target
+930.58%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.19% | 11.52B | |
| +44.16% | 3.27B | |
| -19.90% | 2.02B | |
| -38.37% | 2.03B | |
| -30.21% | 1.44B | |
| +16.18% | 1.01B | |
| -6.11% | 719M | |
| -32.75% | 418M | |
| -52.35% | 339M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
